Tonix Pharmaceuticals To Present Effects Of TONMYA On Fibromyalgia Symptoms And Physical Function At The World Congress On Pain, October 26-30
Benzinga Newsdesk 1 week ago
News
TONMYA was approved by the U.S. Food and Drug Administration on August 15, 2025, and commercially launched in the U.S. on November 17, 2025.Poster Presentation DetailsTitle: Cyclobenzaprine HCl Sublingual Reduces
TONMYA was approved by the U.S. Food and Drug Administration on August 15, 2025, and commercially launched in the U.S. on November 17, 2025.
Poster Presentation Details
Title: Cyclobenzaprine HCl Sublingual Reduces Fibromyalgia Impact on Physical Symptoms & Functional Ability
Poster #: 157
Poster Session: 2
Date: October 27, 2026
Time: 3:15-4:45 p.m. ICT
Presenter: Errol Gould, Ph.D., Senior Vice President, Medical Affairs, Tonix Medicines